Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant.
Shuai XiaJasper Fuk-Woo ChanLijue WangFanke JiaoKenn Ka-Heng ChikHin ChuQiaoshuai LanWei XuQian WangChao WangKwok-Yung YuenLu LuShibo JiangPublished in: Cell research (2022)
Keyphrases